(NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug, Leqembi. The FDA earlier granted Leqembi accelerated approval and now is considering it for traditional approval. The agency is set to make a decision on July 6.

But things may not be so bright in Europe. Alzheimer's disease experts there say Leqembi's clinical benefit may not outweigh the potential side effects and cost to the health system, according to Reuters. Biogen, facing declining revenue in older drugs, is counting on Leqembi to usher in a new era of growth. Could this potential problem in Europe signal trouble?

First, some more details from the Reuters report. Nine neurologists and researchers in Europe who spoke to the wire service each said Leqembi, even if approved, may not be widely prescribed. The general view is the possible side effect of brain swelling along with the cost and logistics of treatment may discourage doctors from prescribing it for their patients.

Continue reading

Source Fool.com